Navigation Links
GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
Date:3/6/2013

ZURICH-SCHLIEREN, Switzerland, March 6, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Greco steps down from the Chairmanship.

Gerd Zettlmeissl has more than 20 years of experience in developing and commercializing vaccines. He spent almost 10 years in executive positions at Intercell AG, first as its Chief Operating Officer from 2001 to 2005 and then as its Chief Executive Officer from 2005 until May  2011. Under his leadership, the company received international approval for the novel Japanese encephalitis vaccine, IXIARO®/JESPECT®, formed major strategic alliances with leading pharmaceutical companies, completed several financings, was elected as 'Technology Pioneer' at the World Economic Forum in 2009 and received the European Biotechnica Award in 2006. Before his tenure at Intercell, he served as the international Head of Industrial and Quality Operations at Chiron Vaccines, and Managing Director of Chiron Behring GmbH & Co. He currently serves on the Boards of several biotechnology companies including Aeras, an organization dedicated to the development of tuberculosis vaccines. He holds a Doctorate from the University of Regensburg.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," said Michel Greco , Chairman of the Board of Directors of GlycoVaxyn. "After having chaired the Board for more than seven years, I will work very closely with Gerd to ensure a smooth transition."

Philippe Dro , Chief Executive Officer of GlycoVaxyn added, "The changes to the Board and the appointment of Gerd will contribute to support GlycoVaxyn's strategic ambitions to become a major player in the development of a new generation of vaccines, particularly following our recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals. We know Gerd very well and share with him a common passion for the development of innovative vaccines. After several years of close collaboration with Michel on this exciting project over the years, I would like to sincerely thank him, on behalf of the whole team, for his strong commitment and support."

About GlycoVaxyn AGGlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoprotein conjugates in a biological process that circumvents many of the challenges and uncertainties involved in currently/chemical used methods. In addition to the clinical stage Shigella vaccine, lead programs in preclinical stage are aimed at the prevention of hospital acquired Staphylococcus aureus infections. GlycoVaxyn recently entered collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals. GlycoVaxyn is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners.  For further information, visit www.glycovaxyn.com.Contacts:Robert FlammGlycoVaxyn AG

Russo Partners, LLCTel: +41 44 733 8595

Tel: +212-845-4226media@glycovaxyn.com

robert.flamm@russopartnersllc.com


'/>"/>
SOURCE GlycoVaxyn AG
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bayer CropScience Announces Seed Innovation at Pollinator Summit
2. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
3. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
4. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
5. Quantum Cures Announces Breakthrough Approach for Researchers Seeking Cures for Orphan and Rare Diseases
6. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
7. Research and Markets Announces Addition of the "Risk - Reward of Developing a Herceptin Biosimilar - A Thorough Assessment" Report to its Offering
8. Research & Markets Announces the Release of 'Analog Devices ADXL362 3-axis Micropower MEMS Accelerometer Reverse Costing Analysis'
9. Research & Markets Announces the Release of STMicroelectronics LSM303D 6-Axis Electronic Compass - Reverse Costing Analysis
10. Pamlab Announces Agreement for Sale of Business to Nestle Health Science
11. Elsevier Announces the Launch of a New Journal: Methods in Oceanography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 24, 2017  Frost & Sullivan is pleased to announce that ... receive special recognition at the 22nd Annual Medical Technologies: A ... 21, 2017 at the Loews Coronado Bay Resort in ... download the event agenda for Medical Technologies 2017: A Frost & ... ...
(Date:1/24/2017)... BILLERICA, Mass. , Jan. 24, 2017 ... acquired Hysitron, Inc., a technology leader in ... test instrumentation. The acquisition adds Hysitron,s innovative ... of atomic force microscopes (AFMs), surface profilometers, ... enhancing Bruker,s leadership position in nanomaterials research ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... circumference, and increased serum leptin levels had a positive association with increased prostate ... study published in the International Neurourology Journal involved 571 Korean men who ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. ... today that its orally active lead drug candidate, PBI-4050, ... by the UK Medicines and Healthcare Products Regulatory Agency ... A PIM designation is an early indication ... the Early Access to Medicines Scheme ("EAMS"), intended for ...
Breaking Biology Technology:
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
Breaking Biology News(10 mins):